# Peter Vermeul’s Post > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/peter-vermeuls-post/ > **Published:** 2026-06-19T12:12:59-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:22:27-04:00 > **Clinical Summary:** Understand whole plant cannabis pharmacology: how cannabinoid acids, terpenes, and entourage effects shape clinical outcomes beyond THC-CBD ratios. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchTHCCBDHempSafetyNeurologyMental Health Why This Matters Clinicians need to understand that cannabis effects depend on multiple plant compounds beyond THC, including cannabinoid acids, terpenes, and flavonoids, which means patient outcomes cannot be predicted from THC content alone. This complexity has direct implications for dosing recommendations, side effect profiles, and therapeutic efficacy, requiring clinicians to ask patients about full product composition rather than relying on potency labels. A more nuanced understanding of cannabis biochemistry enables better informed consent conversations and more individualized treatment decisions for patients considering or using cannabis therapeutically. Clinical Summary Cannabis comprises a complex phytochemical matrix beyond THC alone, including cannabinoid acids, terpenes, flavonoids, and cannflavins, each potentially contributing to clinical effects through distinct pharmacological mechanisms. Clinicians who focus exclusively on THC content when counseling patients or evaluating cannabis products may overlook important bioactive compounds that influence therapeutic outcomes, side effect profiles, and individual patient responses. The acidic precursors of cannabinoids (such as THCA and CBDA) and secondary metabolites like terpenes exhibit their own pharmacological activities, including anti-inflammatory and anxiolytic properties, which may enhance or modify the effects of decarboxylated cannabinoids. This chemical complexity underscores why standardized, full-spectrum product analysis and patient-specific cannabinoid profiling could optimize therapeutic selection and minimize adverse effects. For clinical practice, clinicians should move beyond THC-centric assessment to consider the whole-plant composition when discussing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) with patients, requesting detailed cannabinoid and terpene profiles from dispensaries when available, and recognizing that variable product composition may explain inconsistent patient responses to [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). Dr. Caplan’s Take “What Vermeul is pointing to here is real and clinically relevant: the cannabis plant contains hundreds of compounds, and our research has historically narrowed in on THC and CBD while largely ignoring the pharmacology of cannabinoid acids, terpenes, and [minor cannabinoids](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/). The early signals around compounds like CBGA and specific terpene profiles are worth watching, but we need rigorous human studies before we can make clinical claims about their individual or synergistic effects. For now, whole-plant composition matters more than we once thought, even if we can’t yet prescribe based on those details with confidence.” Clinical Perspective 💊 The cannabis plant’s pharmacological complexity extends well beyond THC, encompassing cannabinoid acids, terpenes, flavonoids, and other phytochemical constituents that may contribute meaningfully to clinical effects. While most [clinical research](https://cedclinic.com/endocannabinoid-system-stroke-prevention/) and regulatory frameworks have focused narrowly on isolated cannabinoids like THC and CBD, emerging evidence suggests that whole-plant preparations or specific terpene-cannabinoid combinations may produce distinct therapeutic profiles through entourage effects, though robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) validating these synergies remain limited. Healthcare providers should recognize that cannabis products encountered in clinical practice vary dramatically in chemical composition depending on cultivation, processing, and extraction methods, making it difficult to standardize dosing or predict individual patient responses. This chemical heterogeneity presents a significant caveat to counseling patients, as the evidence base for isolated compounds cannot necessarily be extrapolated to commercial products patients may purchase. Clinically, providers should consider inquiring about specific 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Peter%20Vermeul%27s%20Post%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59666)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59666)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Peter%20Vermeul%27s%20Post%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59666)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.linkedin.com/posts/peter-vermeul-7792bb247_medicinalcannabis-cannabisextracts-wholeplantextracts-activity-7473489475336077312-xag6](https://www.linkedin.com/posts/peter-vermeul-7792bb247_medicinalcannabis-cannabisextracts-wholeplantextracts-activity-7473489475336077312-xag6) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).